Celcuity (CELC) Expected to Announce Earnings on Wednesday

Key Points

• Celcuity is expected to release its Q2 2025 earnings on August 13th, with analysts predicting earnings of ($0.94) per share.
• In a notable recent transaction, Director David Dalvey sold 100,000 shares of the company’s stock, reducing his ownership by 44.44%.
• Analysts have given Celcuity a consensus target price of $39.20, with several firms issuing "buy" ratings and price targets ranging from $29.00 to $60.00.

Celcuity (NASDAQ:CELC - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Wednesday, August 13th. Analysts expect Celcuity to post earnings of ($0.94) per share for the quarter.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.09. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Price Performance

Shares of Celcuity stock traded up $1.64 on Friday, hitting $45.88. 1,325,977 shares of the company traded hands, compared to its average volume of 2,577,971. Celcuity has a 12-month low of $7.57 and a 12-month high of $48.00. The firm's 50-day simple moving average is $18.60 and its 200 day simple moving average is $13.42. The company has a market cap of $1.79 billion, a P/E ratio of -15.14 and a beta of 0.68. The company has a current ratio of 6.61, a quick ratio of 6.61 and a debt-to-equity ratio of 1.14.

Analyst Upgrades and Downgrades

CELC has been the topic of a number of recent research reports. HC Wainwright upped their price objective on shares of Celcuity from $27.00 to $50.00 and gave the stock a "buy" rating in a report on Monday, July 28th. Needham & Company LLC restated a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research note on Monday, July 28th. Stifel Nicolaus began coverage on Celcuity in a research report on Tuesday, July 1st. They set a "buy" rating and a $30.00 price objective for the company. Finally, Leerink Partners upped their price target on shares of Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research report on Monday, July 28th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $39.20.

Insider Buying and Selling at Celcuity

In other Celcuity news, Director David Dalvey sold 100,000 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the sale, the director directly owned 125,000 shares of the company's stock, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.77% of the company's stock.

Hedge Funds Weigh In On Celcuity

An institutional investor recently bought a new position in Celcuity stock. Creative Planning bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 13,291 shares of the company's stock, valued at approximately $177,000. Institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.